Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-137915
Filing Date
2026-04-01
Accepted
2026-04-01 16:14:56
Documents
16
Period of Report
2026-05-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A vktx-20260401.htm   iXBRL DEF 14A 1489665
2 GRAPHIC img12074702_0.jpg GRAPHIC 103118
3 GRAPHIC img12074702_1.jpg GRAPHIC 83453
4 GRAPHIC img12074702_2.jpg GRAPHIC 180291
5 GRAPHIC img12074702_3.jpg GRAPHIC 172318
  Complete submission text file 0001193125-26-137915.txt   4125139

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20260401.xsd EX-101.SCH 8927
19 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20260401_htm.xml XML 504245
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37355 | Film No.: 26828323
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)